Treatment Approach for Newly Diagnosed Cancer

Chapter 12: Treatment Approach to Newly Diagnosed Prostate Cancer

"So What Happens to Me?"

Chapter Opening — A Survivor's Story

David was 62 when his PSA came back at 7.2 ng/mL. An MRI showed a suspicious lesion, and a biopsy confirmed Grade Group 3 prostate cancer — unfavorable intermediate risk. His urologist recommended surgery. His neighbor, a prostate cancer survivor, told him radiation was better. His brother-in-law said he should "just watch it." David felt paralyzed.

Then his doctor referred him to a multidisciplinary clinic where he met a urologist, a radiation oncologist, and a medical oncologist — all in one visit. They reviewed his scans, his pathology, his overall health, and his priorities. They explained that both surgery and radiation would give him excellent cancer control, but the side effects were different. They asked him what mattered most: avoiding incontinence? Preserving sexual function? Minimizing time off work?

David chose radiation with short-term hormone therapy. Three years later, his PSA is undetectable, he is back to playing golf, and he has no regrets — not because radiation was "better," but because it was the right choice for him.

This chapter is about helping you find YOUR right choice.

Part 1: Before We Talk About Treatment — The Big Picture

If you have read the earlier chapters of this book, you now understand what prostate cancer is, how it is graded and staged, and what imaging can show. This chapter is where all of that knowledge comes together into the most important question: What should I do about my cancer?

The answer is different for every man. No two patients have the same cancer, the same body, or the same priorities. The treatment that is perfect for your neighbor may not be right for you. This is why understanding your own situation — and being an active participant in the decision — is so important.

The Four Pillars of Treatment Decision-Making

Every treatment recommendation is built on four pillars:

1. Your risk group — This is determined by your Gleason score (Grade Group), PSA level, and clinical stage (how far the cancer has spread on exam and imaging). Risk groups range from very low to very high, and each group has different treatment recommendations.¹
2. Your life expectancy — This is not just about age. A healthy 75-year-old may have a longer life expectancy than a 60-year-old with diabetes, heart disease, and obesity. Doctors use validated tools to estimate life expectancy because it directly affects whether treatment benefits outweigh risks.²
3. Your baseline function — How well are your urinary, sexual, and bowel functions working right now? This matters because treatments can affect these functions, and your starting point strongly predicts your outcome. This is why questionnaires like the EPIC-26, SHIM, and IPSS (discussed in Chapter 2) are so important.³
4. Your personal values and preferences — What matters most to you? Some men want the cancer "out" and prefer surgery. Others want to avoid an operation and prefer radiation. Some prioritize preserving sexual function; others prioritize avoiding incontinence. There is no wrong answer.

The Importance of a Multidisciplinary Team

The National Comprehensive Cancer Network (NCCN) guidelines emphasize that treatment decisions for localized prostate cancer should be made in a multidisciplinary manner, with shared decision-making that includes an explanation of the potential benefits and harms of each option.¹ Ideally, you should see:

• A urologist (the surgeon)
• A radiation oncologist (the radiation specialist)
• A medical oncologist (the systemic therapy specialist, especially for advanced disease)

Some cancer centers offer multidisciplinary clinics where you see all three in one visit. If that is not available, make sure you consult with at least a urologist AND a radiation oncologist before making your decision. Studies consistently show that the type of doctor you see first strongly influences the treatment you receive — not because doctors are biased, but because each specialist naturally knows their own treatment best.⁴

Second Opinions Are Your Right

Never feel guilty about seeking a second opinion. Most insurance plans cover it. A second opinion can confirm your diagnosis, sometimes change your risk group (pathology review changes the grade in 25–30% of cases), and give you confidence in your decision.

Clinical Trials: Not a Last Resort

Clinical trials are not experimental treatments for desperate situations. They are carefully designed studies that often offer the newest and most promising therapies — sometimes better than the current standard of care. Ask your doctor if there are any clinical trials appropriate for your situation. You can also search ClinicalTrials.gov yourself.

You Have Time

One of the most important things to understand: for most prostate cancers, you have weeks to months to make a thoughtful decision. Prostate cancer is usually slow-growing. Rushing into treatment leads to regret. Take the time to gather information, get second opinions, and make a decision you are comfortable with.

Part 2: Very Low-Risk and Low-Risk Prostate Cancer

Grade Group 1 (Gleason Score 6) | PSA 10 | Stage T1–T2a

The Bottom Line: Active surveillance is the preferred approach for most patients. This is not "doing nothing" — it is the recommended, evidence-based strategy.

If your biopsy shows Grade Group 1 (Gleason 6) prostate cancer with a PSA below 10 and no concerning findings on exam, you have low-risk prostate cancer. This is the most common type of prostate cancer diagnosed today, and the evidence overwhelmingly supports active surveillance as the best initial approach.⁵ ⁶

Why Active Surveillance Is Preferred

Grade Group 1 prostate cancer has essentially zero metastatic potential when properly monitored. The landmark ProtecT trial followed 1,643 men with PSA-detected localized prostate cancer for 15 years. The results were striking: prostate cancer–specific survival was approximately 97% regardless of whether men received active monitoring, surgery, or radiation.⁷ In other words, the risk of dying from this cancer was very low no matter what treatment was chosen.

Furthermore, 24.4% of men in the active monitoring group were alive at 15 years without ever having received any treatment for their prostate cancer.⁷ This means that nearly one in four men never needed treatment at all.

Active surveillance avoids the side effects of treatment — incontinence, erectile dysfunction, bowel problems — for a cancer that may never threaten your life. It is not "doing nothing." It is a structured program of monitoring with the intention to treat if the cancer changes. (See Chapter 8 for the detailed active surveillance protocol.)

A large multicenter study of 2,155 patients on active surveillance found that at 10 years, 49% remained free of disease progression or treatment, less than 2% developed metastases, and less than 1% died of prostate cancer.⁴

When Might Treatment Be Considered Even in Low-Risk Disease?

The NCCN recognizes that there is heterogeneity within the low-risk group. Some factors may be associated with a higher probability of grade reclassification (meaning the cancer may be more aggressive than the biopsy showed):⁵

• High PSA density (≥0.15 ng/mL/g)
• Multiple positive biopsy cores (e.g., ≥3)
• High genomic risk on tissue-based molecular testing
• Known BRCA2 germline mutation
• Patient anxiety that cannot be managed despite counseling
• Expected poor adherence to follow-up

In some of these cases, upfront treatment with surgery or radiation may be preferred based on shared decision-making.⁵

If Treatment Is Chosen

For low-risk patients who elect treatment:

• Radiation therapy: External beam radiation (EBRT) or brachytherapy (seeds) as monotherapy. No hormone therapy (ADT) is needed. No pelvic lymph node radiation is needed.⁸
• Surgery: Radical prostatectomy with nerve-sparing technique when possible.
• Focal therapy: Only within clinical trials — not yet standard of care.⁹

If Life Expectancy Is Less Than 10 Years

For older men or those with significant medical conditions whose life expectancy is less than 10 years, observation (watchful waiting) is appropriate. This is different from active surveillance: observation means monitoring for symptoms and treating only if the cancer causes problems, without the intention of curative treatment.⁵

Part 3: Favorable Intermediate-Risk Prostate Cancer

Grade Group 1 or 2 | 1 Intermediate Risk Factor | 50% Cores Positive

The Bottom Line: Active surveillance is an option for carefully selected patients. Definitive treatment with surgery or radiation (generally without hormone therapy) is also appropriate.

Favorable intermediate-risk prostate cancer is defined as having one intermediate risk factor (PSA 10–20, or clinical stage T2b–T2c, or Grade Group 2 or 3), with Grade Group 1 or 2, and less than 50% of biopsy cores positive.¹

Active Surveillance in Favorable Intermediate Risk

The NCCN states that patients with favorable intermediate-risk prostate cancer and a life expectancy of more than 10 years may consider active surveillance.¹⁰ However, not all patients in this group are suitable candidates. The favorable intermediate-risk group was not created specifically for selecting active surveillance candidates, and there is considerable heterogeneity.¹⁰

For example:

• A man with Grade Group 1 in a single core, PSA of 12, and low PSA density has favorable intermediate-risk disease and is an excellent candidate for active surveillance.
• A man with Grade Group 2 in 5 of 12 cores with cribriform architecture and high PSA density also has favorable intermediate-risk disease, but active surveillance would NOT be preferred.¹⁰

Active surveillance is NOT recommended for patients with unfavorable histology such as cribriform or intraductal carcinoma.¹⁰ A secondary analysis of the ProtecT trial showed that cribriform-positive disease was a strong predictor of metastasis, while cribriform-negative patients had excellent outcomes regardless of treatment.¹¹

Confirmatory testing (repeat biopsy, MRI, genomic testing) is strongly recommended before committing to active surveillance.¹⁰

If Treatment Is Chosen

• Radiation therapy options:
• EBRT alone — moderate hypofractionation (4–6 weeks) is preferred over conventional fractionation (8–9 weeks).⁸ ¹² SBRT (1–2 weeks) is also acceptable based on the PACE-B and HYPO-RT-PC trials.¹³ ¹⁴
• Brachytherapy monotherapy (LDR seeds or HDR) is also an option.
• Hormone therapy (ADT) is generally NOT recommended, but can be considered if additional risk assessments suggest aggressive tumor behavior.⁸
• No pelvic lymph node radiation is needed.
• Combination brachytherapy boost with EBRT should NOT be used for this risk group.⁸
• Surgery: Radical prostatectomy with nerve-sparing technique.
• Focal therapy: Only within clinical trials.⁹

Choosing Between Surgery and Radiation

For favorable intermediate-risk disease, cancer control outcomes are equivalent at 10–15 years.⁷ ¹⁵ ¹⁶ The choice comes down to side effects and personal preference. (See Part 7 of this chapter for a detailed comparison.)

If Life Expectancy Is 5–10 Years

Observation is the preferred approach. Treatment with surgery or radiation is also an option.¹

Part 4: Unfavorable Intermediate-Risk Prostate Cancer

Grade Group 2 with Unfavorable Features, or Grade Group 3 | ≥50% Cores Positive | 2–3 Intermediate Risk Factors

The Bottom Line: Definitive treatment is recommended. Active surveillance is NOT recommended for patients with more than 10 years of life expectancy.

Unfavorable intermediate-risk prostate cancer is defined as having 2 or 3 intermediate risk factors, OR Grade Group 3, OR 50% or more of biopsy cores positive.¹ This is where treatment becomes more important — the risk of progression is meaningfully higher than in favorable intermediate-risk disease.

The NCCN explicitly states: active surveillance of unfavorable intermediate and high-risk clinically localized cancers is not recommended in patients with a life expectancy greater than 10 years (Category 1 recommendation).¹⁷

Radiation Therapy Options

• EBRT + short-term ADT (4–6 months) — This is the standard approach. Multiple randomized trials have demonstrated that adding short-term ADT to radiation improves outcomes in this risk group.⁸ ¹⁸
• ADT should be used as a concurrent and adjuvant approach with radiation, rather than neoadjuvant and concurrent.⁸
• Radiotherapy dose or modality has not clearly demonstrated the ability to eliminate the benefit of ADT.⁸
• Brachytherapy monotherapy is an option. Multiple randomized trials that included patients with unfavorable intermediate risk did not demonstrate superiority of combination therapy (EBRT + brachy boost) over brachytherapy monotherapy.⁸
• EBRT with brachytherapy boost is also an option for dose escalation.
• SBRT is acceptable. The PACE-B trial demonstrated that 5-fraction SBRT was non-inferior to conventional or moderately hypofractionated radiotherapy, with 5-year freedom from biochemical or clinical failure of 96% for SBRT and 95% for control radiotherapy.¹³ The HYPO-RT-PC trial confirmed non-inferiority of 7-fraction ultra-hypofractionation at 10 years of follow-up.¹⁴ The newer PACE-C trial is evaluating SBRT specifically in intermediate and high-risk patients receiving ADT, with early toxicity results showing similar RTOG grade 2+ genitourinary and gastrointestinal toxicity between SBRT and moderate hypofractionation.¹⁹
• Moderate hypofractionation (e.g., 60 Gy in 20 fractions over 4 weeks) is preferred over conventional fractionation based on the CHHiP, PROFIT, and RTOG 0415 trials.⁸ ¹²
• Focal boosting to the dominant intraprostatic lesion can be considered if there is sufficient provider expertise.⁸
• Elective nodal irradiation (ENI) should not be used routinely.⁸

Surgery

Radical prostatectomy with or without pelvic lymph node dissection is an appropriate alternative. Nerve-sparing should be performed when oncologically safe. Important to know: there is a chance of needing additional treatment after surgery if adverse features are found on the surgical pathology report (positive margins, extracapsular extension, seminal vesicle invasion). This is discussed in detail in Chapter 13.

Choosing Between Surgery and Radiation

The same principles apply as for favorable intermediate-risk disease. A systematic review of 7 randomized clinical trials comparing radiation therapy versus radical prostatectomy found similar overall survival, cancer-specific survival, and disease-free survival between the two approaches.¹⁵ The Lancet 2026 review confirmed that 15-year prostate cancer-specific survival approaches 97% with either modality.¹⁶

The key difference: with radiation for unfavorable intermediate-risk disease, short-term ADT (4–6 months) is typically added. With surgery, there is a chance of needing radiation afterward if adverse pathology is found. Neither approach is clearly superior.⁴ ¹⁵

If Life Expectancy Is 5–10 Years and Asymptomatic

Observation is an option, but treatment should be considered if the patient becomes symptomatic.¹

Part 5: High-Risk and Very High-Risk Prostate Cancer

Grade Group 4 or 5 | PSA >20 | Stage T3–T4

The Bottom Line: Multimodal treatment is the standard of care. This is NOT a death sentence — many men are cured with aggressive treatment.

High-risk prostate cancer is defined as having one or more of the following: Grade Group 4 or 5, PSA greater than 20 ng/mL, or clinical stage T3–T4.¹

Very high-risk prostate cancer is defined as having at least two of the above features, or PSA greater than 40 ng/mL.¹

These cancers require more aggressive treatment, but the outcomes can still be excellent. Do not lose hope — many men with high-risk prostate cancer are cured.

Important First Step: Staging Imaging

Before any treatment decision, staging imaging (bone scan, CT, or PET scan) is required to rule out metastatic disease.¹ If lymph nodes are found positive on imaging, see Part 6 (Regional Disease). If distant metastases are found, see Part 8 (Metastatic Disease).

Radiation Therapy + Long-Term ADT (Category 1 Recommendation)

The standard approach for high-risk and very high-risk prostate cancer is radiation therapy combined with long-term hormone therapy (ADT) for 12–36 months.²⁰ This is a Category 1 recommendation, meaning it is based on the highest level of evidence with uniform expert consensus.

• Radiation targets: Prostate + seminal vesicles + consideration of pelvic lymph nodes.
• Brachytherapy boost can be added to EBRT for dose escalation.
• ADT duration: 12–36 months (most commonly 24 months). The optimal duration depends on the specific risk features.
• For very high-risk disease: Addition of abiraterone to ADT + radiation can be considered.²⁰
• Fractionation: Conventional fractionation or moderate hypofractionation. SBRT is acceptable for high-risk disease but has less data for very high-risk disease.⁸ ²¹

Surgery

Radical prostatectomy with pelvic lymph node dissection can be considered in patients who are younger and healthier without tumor fixation to the pelvic sidewall.¹⁷ Important considerations:

• Nerve-sparing may not be possible depending on tumor extent.
• There is a higher chance of needing additional treatment afterward (radiation ± ADT) if adverse features are found on surgical pathology.
• Surgery is not preferred for patients with fixed tumors (T4 disease).

If Life Expectancy Is 5 Years or Less and Asymptomatic

Observation is an option. Alternatively, radiation with or without ADT can be considered.²⁰ Monitoring is not preferred for patients with multiple high-risk features.¹⁷

A Word of Encouragement

A diagnosis of high-risk prostate cancer is frightening, but it is important to understand that "high risk" does not mean "incurable." With modern multimodal treatment — radiation combined with long-term hormone therapy, or surgery followed by additional treatment if needed — many men achieve long-term cancer control. The key is getting the right treatment from the start.

References

1. 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026.
2. 2. National Comprehensive Cancer Network. Principles of Life Expectancy Estimation (PROS-A). Version 5.2026.
3. 3. Hoffman KE, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323(2):149–163.
4. 4. Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333(16):1433–1446.
5. 5. National Comprehensive Cancer Network. Principles of Active Surveillance and Observation (PROS-F). Version 5.2026.
6. 6. National Comprehensive Cancer Network. Low-Risk Group: Initial Therapy (PROS-3). Version 5.2026.
7. 7. Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547–1558.
8. 8. National Comprehensive Cancer Network. Principles of Radiation Therapy (PROS-J). Version 5.2026.
9. 9. National Comprehensive Cancer Network. Principles of Focal/Subtotal Therapy (PROS-I). Version 5.2026.
10. 10. National Comprehensive Cancer Network. Principles of Active Surveillance — Favorable Intermediate Risk (PROS-F 2 of 5). Version 5.2026.
11. 11. Sushentsev N, et al. Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: a secondary analysis of the ProtecT randomized clinical trial. JAMA Oncol. 2025;11(12):1512–1517.
12. 12. National Comprehensive Cancer Network. Principles of Radiation Therapy — Hypofractionation (PROS-J). Version 5.2026.
13. 13. van As N, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer (PACE-B). N Engl J Med. 2024;391(15):1413–1425.
14. 14. Nilsson P, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes. Lancet Oncol. 2026;27(3):293–301.
15. 15. Hekman L, et al. A systematic review of clinical trials comparing radiation therapy versus radical prostatectomy in prostate cancer. Clin Genitourin Cancer. 2024;22(5):102157.
16. 16. Fonteyne V, et al. Prostate cancer. Lancet. 2026;407(10528):622–636.
17. 17. National Comprehensive Cancer Network. Footnotes on PROS-7A. Version 5.2026.
18. 18. National Comprehensive Cancer Network. Unfavorable Intermediate-Risk Group: Initial Therapy (PROS-5). Version 5.2026.
19. 19. Tree AC, et al. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results. Lancet Oncol. 2025;26(7):936–947.
20. 20. National Comprehensive Cancer Network. High- or Very-High-Risk Group: Initial Therapy (PROS-6). Version 5.2026.
21. 21. National Comprehensive Cancer Network. Principles of Radiation Therapy — SBRT (PROS-J). Version 5.2026.

Chapter 13b: Treatment Approach to Newly Diagnosed Prostate Cancer — Parts 6–11 and Chapter Elements

Chapter 12 (Continued): Treatment Approach to Newly Diagnosed Prostate Cancer

Part 6: Regional (Node-Positive) Prostate Cancer — Any T, N1, M0

The Bottom Line: Cancer has spread to nearby lymph nodes in the pelvis, but NOT to distant sites. This is still a curable disease for many patients. Treatment is more intensive but outcomes can be excellent.

If your imaging or biopsy shows that prostate cancer has spread to the pelvic lymph nodes but not to distant sites (bones, liver, lungs), you have what doctors call "regional" or "node-positive" prostate cancer. This is more advanced than localized disease, but it is NOT the same as metastatic cancer, and many men with this diagnosis are cured.¹

How Is Node-Positive Disease Found?

Node-positive disease can be discovered in two ways:

• On imaging before treatment: A CT scan, MRI, or PET scan shows enlarged or suspicious lymph nodes in the pelvis.
• At the time of surgery: The surgeon removes pelvic lymph nodes during a radical prostatectomy, and the pathologist finds cancer in one or more of them. This is sometimes unexpected.

Treatment Options

For patients with more than 5 years of life expectancy or who have symptoms:¹

• Radiation therapy + long-term ADT (24 months) + abiraterone — This is the preferred approach. Radiation is delivered to the prostate, seminal vesicles, and pelvic lymph nodes. ADT is given for 24 months, and abiraterone is added to improve outcomes.¹
• Radiation therapy + long-term ADT (24–36 months) without abiraterone — Also an appropriate option.¹
• ADT with or without abiraterone alone (without radiation) — An option, but generally less preferred because radiation provides additional local control.¹
• Surgery (radical prostatectomy) in select patients — Limited to patients with more than 10 years of life expectancy and resectable disease. An extended pelvic lymph node dissection is performed. After surgery, additional treatment (radiation and/or ADT) may be needed depending on the pathology findings.¹

For patients with 5 years or less of life expectancy and no symptoms:¹

• Observation or radiation therapy alone
• ADT with or without radiation therapy

If Node-Positive Disease Is Found Unexpectedly at Surgery

If the surgeon removes lymph nodes during a prostatectomy and the pathologist finds cancer in them, the treatment team will discuss whether additional treatment is needed. Options include adjuvant ADT with or without radiation therapy. This decision depends on the number of positive nodes, the extent of cancer in the nodes, and other pathology findings.

Part 7: Surgery vs. Radiation — A Head-to-Head Comparison for the Patient

The Bottom Line: For most patients with localized prostate cancer, surgery and radiation produce equivalent cancer control. The choice comes down to side effects, personal values, and individual circumstances.

This is the question that keeps men up at night: "Should I have surgery or radiation?" The honest answer, supported by the best available evidence, is that both treatments produce excellent and equivalent cancer control for most patients. The real differences are in the side effects.

What Does the Evidence Say?

The strongest evidence comes from randomized controlled trials — studies where patients are randomly assigned to one treatment or the other, eliminating bias:

• The ProtecT Trial (15 years of follow-up): This landmark British trial followed 1,643 men with PSA-detected localized prostate cancer for 15 years. Prostate cancer–specific survival was approximately 97% regardless of whether men received active monitoring, surgery, or radiation. There was no statistically significant difference in prostate cancer mortality between the three groups.²
• A systematic review of 7 randomized trials comparing radiation therapy versus radical prostatectomy found similar overall survival, cancer-specific survival, and disease-free survival between the two approaches.³
• The Lancet 2026 comprehensive review confirmed that 15-year prostate cancer-specific survival approaches 97% with either surgery or radiation for localized disease.⁴
• A 2025 JAMA review noted that for clinically localized prostate cancer, treatment options include active surveillance, radical prostatectomy, and radiation therapy, with similar long-term cancer control outcomes.⁵

Side Effect Comparison

While cancer control is equivalent, the side effects are different. Understanding these differences is key to making the right decision for YOU:

Urinary function:

• After surgery, some degree of urinary leakage (incontinence) is common in the first weeks to months. Most men recover good urinary control within 6–12 months, but 5–15% may have persistent leakage requiring pads.
• After radiation, urinary incontinence is uncommon. However, some men experience urinary frequency, urgency, or burning during and shortly after treatment. These symptoms usually improve over weeks to months. Late urinary stricture (narrowing) can occur in a small percentage.

Sexual function:

• After surgery, erectile dysfunction is common even with nerve-sparing technique. Recovery depends on age, baseline function, and whether nerves were preserved. It can take 12–24 months for erections to return, and some men need medications or devices.
• After radiation, erectile function is usually preserved in the short term but may gradually decline over 2–5 years. The decline is slower and more gradual than after surgery.

Bowel function:

• After surgery, bowel function is generally not affected.
• After radiation, some men experience increased bowel frequency, urgency, or rectal bleeding. Modern techniques (IMRT, IGRT, rectal spacers) have significantly reduced these risks. Severe bowel problems are uncommon with current technology.

Other considerations:

• Surgery provides a complete pathology report of the entire prostate, which gives additional information about the cancer (margins, extracapsular extension, seminal vesicle invasion, lymph node status). This information can guide decisions about whether additional treatment is needed.
• Radiation avoids the risks of surgery (anesthesia, bleeding, infection, blood clots) and does not require hospitalization.
• After surgery, if the cancer returns, radiation can be used as a "backup" (salvage radiation). After radiation, if the cancer returns locally, salvage options exist but are more complex (see Chapter 13).

Factors That May Favor Surgery

• Younger age (longer time to benefit from the pathology information)
• Large prostate causing significant urinary obstruction (surgery removes the obstruction)
• Preference to "get it out"
• Desire to avoid hormone therapy (which is often added to radiation for intermediate and high-risk disease)
• Prior pelvic radiation for another condition

Factors That May Favor Radiation

• Older age or significant medical conditions that increase surgical risk
• Preference to avoid surgery and anesthesia
• Desire to preserve sexual function in the short term
• Prior abdominal surgery that makes prostatectomy more complex
• Smaller prostate (easier to treat with radiation)

The Most Important Advice

See BOTH a urologist AND a radiation oncologist before making your decision. Studies consistently show that the type of doctor you see first strongly influences the treatment you receive. Getting both perspectives ensures you make a truly informed choice.⁵

There is no "better" treatment — only the better treatment for YOU.

Part 8: Metastatic Hormone-Sensitive Prostate Cancer (mCSPC / mHSPC)

The Bottom Line: Metastatic prostate cancer is NOT immediately fatal. Modern combination treatments have dramatically improved survival. Treatment intensification is the standard of care.

If your cancer has spread beyond the prostate and regional lymph nodes to distant sites — most commonly bones, distant lymph nodes, and less commonly liver or lungs — you have metastatic prostate cancer. This is a serious diagnosis, but it is important to understand that modern treatments have dramatically improved outcomes. Many men with metastatic prostate cancer live for years, and the treatments keep getting better.

8A: Understanding Metastatic Disease

Metastatic hormone-sensitive prostate cancer (mHSPC or mCSPC) means the cancer has spread but has not yet been treated with hormone therapy, or the cancer still responds to hormone therapy. This is different from castration-resistant prostate cancer (CRPC), which is discussed in Chapter 10.⁶

Two important classifications:

• De novo (synchronous): The cancer is already metastatic when first diagnosed. This is found in about 5% of all prostate cancer diagnoses. These patients tend to have a worse prognosis than those whose cancer returns after prior treatment.⁴ ⁶
• Recurrent (metachronous): The cancer was initially treated (with surgery or radiation) and later returns in distant sites. These patients generally have a somewhat better prognosis.⁶

Volume matters — a lot:

• Low-volume disease: Fewer than 4 bone metastases without lesions beyond the spine and pelvis, and no visceral (organ) metastases. This was defined by the CHAARTED trial.⁷
• High-volume disease: 4 or more bone metastases with at least 1 beyond the spine and pelvis, OR visceral metastases (liver, lung).⁷
• Oligometastatic disease: A special category with only 1–5 metastases. These patients may benefit from additional targeted treatments to the metastatic sites (see section 8E).⁸ ⁹

8B: The Foundation — Androgen Deprivation Therapy (ADT)

ADT is the backbone of ALL metastatic prostate cancer treatment. It works by lowering testosterone to very low levels (called "castrate levels"), because prostate cancer cells need testosterone to grow.

However — and this is critically important — ADT alone is no longer sufficient. The NCCN guidelines strongly recommend combination therapy for metastatic disease. ADT monotherapy is discouraged unless there are clear contraindications to combination therapy.¹⁰ ¹¹

Castration resistance (when the cancer learns to grow despite very low testosterone) typically develops within 12–24 months on ADT alone, with a median overall survival of about 36 months.⁶ Combination therapy delays this progression and improves survival.

8C: Treatment Intensification — Doublet and Triplet Therapy

The treatment of metastatic prostate cancer has been revolutionized over the past decade. Instead of ADT alone, doctors now add one or two additional medications to improve survival.

Doublet therapy (ADT + one additional agent):

This means adding one of the following medications to ADT:¹⁰ ¹¹

• Abiraterone (Zytiga) — blocks testosterone production at multiple sites
• Enzalutamide (Xtandi) — blocks the testosterone receptor
• Apalutamide (Erleada) — blocks the testosterone receptor
• Darolutamide (Nubeqa) — blocks the testosterone receptor

These are called androgen receptor pathway inhibitors (ARPIs). Multiple large randomized trials (LATITUDE, TITAN, ARCHES, ENZAMET, ARANOTE) have shown that adding any of these to ADT significantly improves survival compared to ADT alone.⁶ ¹²

All four ARPIs are appropriate choices. The decision between them depends on side effect profiles, drug interactions, cost, and patient preference.

Triplet therapy (ADT + ARPI + docetaxel chemotherapy):

For patients who are fit enough for chemotherapy, adding docetaxel (6 cycles of intravenous chemotherapy given every 3 weeks) to ADT + ARPI can further improve outcomes. This is called "triplet therapy."¹³ ¹⁴

The key evidence:

• ARASENS trial: Adding darolutamide to ADT + docetaxel improved overall survival compared to ADT + docetaxel alone (HR 0.68), meaning a 32% reduction in the risk of death. Benefits were seen across high-volume and low-volume subgroups.¹² ¹⁴
• PEACE-1 trial: Adding abiraterone to ADT + docetaxel improved overall survival (HR 0.75 in the overall population, HR 0.72 in high-volume disease).¹⁴ ¹⁵
• ENZAMET trial: Adding enzalutamide to ADT improved overall survival regardless of whether docetaxel was also used.¹²

An important nuance: while triplet therapy (ADT + ARPI + docetaxel) is clearly superior to ADT + docetaxel, it is unknown whether triplet therapy is superior to ADT + ARPI alone (doublet with an ARPI).⁵ ¹⁴ A 2026 network meta-analysis found that no triplet regimen demonstrated a statistically significant overall survival benefit over ARPI doublet in the overall population, although triplet therapy significantly improved overall survival in the high-volume subgroup (HR 0.76).¹⁶ Therefore, both doublet (ADT + ARPI) and triplet (ADT + ARPI + docetaxel) are guideline-recommended options.⁵ ¹⁰

For high-volume disease: Triplet therapy is preferred for patients who are fit for chemotherapy.¹⁰ ¹¹ ¹⁷

For low-volume disease: ADT + ARPI (doublet) is generally preferred. Triplet therapy is an option but the additional benefit over doublet is less clear.⁵ ¹⁰ ¹⁶

For BRCA2-mutated mCSPC: An additional option is ADT + niraparib + abiraterone, based on a randomized phase 3 trial showing improved radiographic progression-free survival in the BRCA-mutated population.¹⁰ ¹³

8D: Radiation to the Prostate in Metastatic Disease

This is one of the most exciting developments in prostate cancer treatment: even when cancer has spread, treating the prostate with radiation can improve outcomes.

Traditionally, doctors believed that once cancer had spread, treating the prostate was pointless. This thinking has been overturned by two landmark trials:

• STAMPEDE trial (UK/Switzerland): This trial randomly assigned men with newly diagnosed metastatic prostate cancer to standard treatment with or without radiation to the prostate. In the overall population, radiation did not improve overall survival. However, in men with low-volume disease, radiation improved overall survival by 36% (HR 0.64), without any detriment in quality of life. Long-term follow-up at 61 months confirmed this benefit.¹⁸ ¹⁹ Radiation was delivered as either 55 Gy in 20 fractions over 4 weeks or 36 Gy in 6 weekly fractions.²⁰
• PEACE-1 trial (Europe): This trial tested the addition of radiation and/or abiraterone to ADT ± docetaxel. In patients with low-volume disease receiving abiraterone, adding radiation improved radiographic progression-free survival (median 7.5 years vs. 4.4 years). Radiation also delayed the onset of castration resistance and reduced serious urinary events, regardless of disease volume — all without increasing overall toxicity.²¹ ²²

A meta-analysis of these trials confirmed that prostate radiation should be considered for men with mHSPC and low metastatic burden, providing approximately 7% improvement in 3-year survival.²³

Based on this evidence:¹⁰ ²⁴

• Low-volume disease: Radiation to the prostate is RECOMMENDED as part of the treatment plan, combined with ADT + ARPI.
• High-volume disease: Radiation to the prostate can be considered. While it did not improve overall survival in this group, it delayed castration resistance and reduced serious urinary events.²¹

8E: Oligometastatic Disease and Metastasis-Directed Therapy (MDT)

Oligometastatic prostate cancer — having only 1 to 5 metastases — represents a special category between localized and widely metastatic disease. For these patients, treating the individual metastatic sites (called metastasis-directed therapy, or MDT) may improve outcomes.⁸ ⁹

MDT is most commonly delivered as SBRT (stereotactic body radiation therapy) — highly focused, high-dose radiation delivered in 1 to 5 treatments to each metastatic site.⁸

Metachronous oligorecurrent disease (cancer returns in a few spots after prior treatment):

This is the setting with the strongest evidence for MDT:

• STOMP trial: MDT (surgery or SBRT) delayed the need for ADT compared to observation in men with oligometastatic castration-sensitive prostate cancer.²⁵
• ORIOLE trial: SBRT significantly reduced progression at 6 months compared to observation (19% vs. 61%). Consolidation of all PSMA-positive disease further decreased the risk of new lesions.²⁵
• EXTEND trial: MDT combined with intermittent ADT improved progression-free survival compared to ADT alone. The combined analysis showed improvements in radiographic progression-free survival and castration resistance-free survival.²⁶
• RADIOSA trial: Adding 6 months of short-course ADT to SBRT improved clinical progression-free survival compared to SBRT alone in oligorecurrent hormone-sensitive prostate cancer.²⁷

The NCCN guidelines list MDT as a preferred option for metachronous oligorecurrent mCSPC and as acceptable for oligometastatic mCRPC.⁸

The WOLVERINE meta-analysis — the most comprehensive analysis to date — combined individual patient data from all published randomized trials of MDT in oligometastatic prostate cancer (472 patients from STOMP, ORIOLE, EXTEND, SABR-COMET, and ARTO). MDT significantly improved progression-free survival (HR 0.44), radiographic progression-free survival (HR 0.60), and castration resistance-free survival (HR 0.58). Overall survival showed a near-significant improvement (HR 0.63, p=0.051), with 4-year overall survival of 87% with MDT vs. 75% without. The benefit of MDT persisted across the entire oligometastatic disease spectrum — from de novo to metachronous, and from castration-sensitive to castration-resistant.⁹ ²⁸

Synchronous oligometastatic disease (found at diagnosis with few metastases):

These patients are treated as low-volume mCSPC with systemic therapy + radiation to the prostate. The addition of MDT to metastatic sites can be considered but has less evidence than the metachronous setting.⁸ ²⁹

Phase 3 trials are ongoing to further define the role of MDT, including START-MET and PRESTO.³⁰

8F: Palliative Radiation

For patients with painful bone metastases, spinal cord compression, or bleeding from the prostate, radiation therapy can provide quick and effective symptom relief. This is called palliative radiation and is different from the curative-intent treatments discussed above.

Palliative radiation:

• Can often be delivered in a single treatment or a short course (1–5 treatments)
• Provides pain relief in 60–80% of patients
• Does not replace systemic therapy — it is used alongside it
• Is discussed in more detail in Chapter 10 (Systemic Therapy) alongside radiopharmaceuticals such as Radium-223 and Lutetium-177 PSMA

Part 9: Choosing Your Radiation Fractionation — A Patient-Friendly Guide

If you and your doctor have decided that radiation therapy is the right treatment for you, the next question is: what type of radiation, and how many treatments?

Radiation for prostate cancer can be delivered in different schedules, called "fractionation." The total dose of radiation is the same — it is just divided into different numbers of treatments:

Conventional fractionation:

• 1.8–2 Gy (a unit of radiation dose) per day
• 37–45 treatments over 8–9 weeks
• This was the standard for decades but is no longer the preferred approach for most patients.³¹

Moderate hypofractionation (PREFERRED):

• 2.5–3.4 Gy per day
• 20–28 treatments over 4–6 weeks
• Multiple large randomized trials (CHHiP, PROFIT, RTOG 0415) have proven this is equally effective and equally safe as conventional fractionation, with the advantage of fewer treatments.³¹ ³²
• This is now the preferred fractionation for most patients receiving external beam radiation.³¹

Ultra-hypofractionation / SBRT:

• 6–9.5 Gy per treatment
• 4–7 treatments over 1–2.5 weeks
• The PACE-B trial demonstrated that 5-fraction SBRT was non-inferior to conventional or moderately hypofractionated radiotherapy, with 5-year freedom from biochemical or clinical failure of 96%.³³
• The HYPO-RT-PC trial confirmed non-inferiority of 7-fraction ultra-hypofractionation at 10 years of follow-up, with failure-free survival of 84% for ultra-hypofractionation vs. 84% for conventional fractionation.³⁴
• SBRT is acceptable for low-risk, favorable intermediate-risk, and unfavorable intermediate-risk disease. It is also acceptable for high-risk disease, though with less long-term data for very high-risk patients.³¹ ³⁵

Brachytherapy:

• LDR (low-dose-rate) permanent seeds: Tiny radioactive seeds are permanently implanted into the prostate in a single outpatient procedure. The seeds deliver radiation over weeks to months and become inactive over time.
• HDR (high-dose-rate) temporary: Thin catheters are temporarily placed into the prostate, a high-dose radioactive source is threaded through them to deliver treatment, and the catheters are removed. This is typically done in 1–2 sessions.
• Brachytherapy can be used alone (monotherapy) for low-risk and favorable intermediate-risk disease, or as a "boost" combined with external beam radiation for higher-risk disease.³¹

Proton beam therapy:

• Uses protons instead of X-rays to deliver radiation
• Theoretically reduces radiation dose to surrounding tissues
• Acceptable but NOT proven superior to standard photon-based IMRT in randomized trials³¹
• Often significantly more expensive and may not be covered by all insurance plans
• Should be discussed openly with your radiation oncologist, including the financial implications

How to choose: The decision depends on convenience (fewer trips to the treatment center), side effect profile, availability at your treatment center, insurance coverage, and your personal preference. Discuss all options with your radiation oncologist.

Part 10: What Happens After Treatment — Follow-Up and PSA Monitoring

Treatment is finished — now what? Follow-up after treatment is a critical part of your prostate cancer journey. Regular monitoring allows your doctor to detect any recurrence early, when it is most treatable.

After Surgery (Radical Prostatectomy):

• PSA should be checked at approximately 6 weeks after surgery. Because the entire prostate has been removed, PSA should drop to undetectable levels (essentially zero).¹³
• After that, PSA is monitored every 6–12 months for the first 5 years, then annually.¹⁴ The AUA/ASTRO guideline recommends more frequent monitoring initially — every 3–6 months for the first 2 years, then every 6 months through year 5, then annually.¹⁶
• A stable PSA of 0.2 ng/mL or less may indicate retained benign prostate tissue and is not necessarily cancer.¹³
• Biochemical recurrence after surgery is defined as a PSA that does not fall to undetectable levels (PSA persistence), OR an undetectable PSA that later rises and increases on 2 or more determinations, OR increases to greater than 0.1 ng/mL.¹⁷ ²⁶ The AUA defines it as a PSA ≥0.2 ng/mL with a confirmatory value >0.2 ng/mL.²⁵
• If PSA recurrence is detected, imaging (PSMA PET-CT is preferred) and risk stratification are performed to determine the best next step.²¹ ²⁸ This is discussed in detail in Chapter 13.
• Important reassurance: Not all patients with biochemical recurrence will die of prostate cancer. Even without salvage treatment, 10-year metastasis-free survival rates are up to 86%, and prostate cancer-specific mortality is only about 5%.²³ ²⁸

After Radiation Therapy:

• PSA monitoring follows the same schedule: every 6–12 months for 5 years, then annually.¹⁴
• Unlike after surgery, the prostate is still in your body. PSA does NOT drop to zero. Instead, it declines slowly over months to years. The target is generally a PSA below 1.0 ng/mL, and the nadir (lowest point) may not be reached for 2–5 years.²⁰
• PSA bounce — a temporary rise in PSA that is NOT recurrence — occurs in about 25–30% of men. This was discussed in detail in Chapter 10. Do not panic if your PSA goes up temporarily.
• Biochemical recurrence after radiation is defined by the Phoenix definition: PSA nadir + 2.0 ng/mL.¹⁹ ²⁹ However, a recurrence evaluation should be considered when PSA is confirmed to be increasing even if the rise above nadir is less than 2 ng/mL, especially in younger, healthier patients who are candidates for secondary local therapy.¹⁹ ²⁹
• If recurrence is suspected, imaging and biopsy may be performed. Treatment options for recurrence after radiation are discussed in Chapter 13.

After Metastatic Disease Treatment:

• Monitoring is more frequent: physical exam and PSA every 3–6 months, with imaging for symptoms or increasing PSA.¹⁴
• The goal is to detect progression early so that treatment can be adjusted.
• Castrate levels of testosterone should be documented if clinically indicated.¹⁹

What to Bring to Follow-Up Visits:

• A list of any new symptoms (urinary, bowel, sexual, pain, fatigue)
• Your current medications
• Questions you want to ask
• Your EPIC-26 or other quality-of-life questionnaire (if your doctor uses one)
• A family member or friend for support, if desired

Part 11: Special Considerations

Young Men (Under 55)

Prostate cancer in younger men presents unique challenges:

• Emotional impact: A cancer diagnosis at a young age can be devastating. Concerns about sexual function, fertility, career, and family are amplified.
• Treatment decisions are harder: Younger men have more years to live with both the cancer and the side effects of treatment. This makes the choice between active surveillance and treatment particularly difficult.
• Active surveillance is underutilized in young men. A 2026 analysis of over 103,000 men with low/very low-risk prostate cancer found that 45% of men under age 59 pursued definitive treatment, compared to only 30% of men over 71 — despite guidelines recommending active surveillance for this risk group. Young age was an independent predictor of receiving treatment, irrespective of other clinicopathologic factors.⁴³
• Fertility preservation: If hormone therapy (ADT) is needed, sperm banking should be discussed BEFORE starting treatment, as ADT suppresses sperm production.
• Genetic testing: Younger men with prostate cancer are more likely to carry hereditary mutations (BRCA1, BRCA2, [Lynch syndrome](/rare-disease/lynch-syndrome)). Genetic counseling and testing should be offered.

Older Men (Over 75) and Men with Significant Comorbidities

• Life expectancy is the key factor. For men with less than 10 years of life expectancy, the risks of treatment often outweigh the benefits for low and intermediate-risk disease. Active surveillance or observation is usually preferred.
• Competing risks: Older men are more likely to die from heart disease, stroke, or other conditions than from prostate cancer. This is called "competing mortality."
• If treatment is needed: Both surgery and radiation can be performed safely in older men, but the decision should account for baseline function, frailty, and personal goals.
• Avoid overtreatment: The goal is to treat cancer that threatens life or quality of life, not cancer that would never cause harm.

Men with Inflammatory Bowel Disease (IBD)

Men with IBD (Crohn's disease or ulcerative colitis) face special considerations:

• Higher prostate cancer risk: A large study found that men with IBD had nearly 5 times the rate of prostate cancer compared to matched controls (4.4% vs. 0.65% at 10 years), including higher rates of clinically significant disease.⁴⁸
• Radiation concerns: Historically, radiation was avoided in IBD patients due to fear of bowel toxicity. However, modern evidence suggests that radiation can be used safely:
• A multicenter study found that IBD flares were about 2-fold higher in the first year after radiation, but there were no differences in IBD-related hospitalizations or surgeries. The authors concluded that avoidance of radiation therapy in IBD patients is likely not necessary.⁴⁷
• A study of 31 IBD patients treated with SBRT found that high-grade toxicities were rare (only 1 case of grade 3 proctitis), and the authors concluded that modern radiation techniques appear to have mitigated the risk of GI side effects.⁴⁶
• IMRT and SBRT are preferred over older techniques due to better bowel sparing.³⁷ ⁴⁴
• Surgery may be preferred in some IBD patients, particularly those with active rectal disease.⁴⁰
• Multidisciplinary approach is essential: Gastroenterologists should be involved in treatment planning alongside urologists and radiation oncologists.³⁷

Men Without a Rectum (Prior Abdominoperineal Resection)

• Transrectal biopsy is not possible; transperineal biopsy is used instead.
• Radiation planning may be different due to altered anatomy, but treatment is still feasible.
• Surgery remains an option.

Men with Prior TURP (Transurethral Resection of the Prostate)

• Prior TURP creates a cavity in the prostate that can affect both brachytherapy seed placement and radiation planning.
• LDR brachytherapy is generally NOT recommended after TURP due to the risk of urinary incontinence from the altered anatomy.
• EBRT and SBRT can still be used, though the radiation oncologist will account for the TURP defect in planning.
• Surgery is still an option, though the altered anatomy may affect the surgical approach.

Aggressive Variants

• Small cell / neuroendocrine prostate cancer: This is a rare, aggressive variant that does not produce PSA and does not respond to hormone therapy. It is treated with chemotherapy (typically platinum-based regimens similar to [small cell lung cancer](/rare-disease/small-cell-lung-cancer)). Radiation may be used for local control.
• Ductal adenocarcinoma: A variant that may present with urinary symptoms and hematuria. It is generally treated similarly to high-grade acinar adenocarcinoma.
• Sarcoma of the prostate: Extremely rare. Treated with surgery and/or chemotherapy. Radiation may play a role.

Prostate Cancer in Gender Minorities (Transgender Women)

• Transgender women who were assigned male at birth still have a prostate and can develop prostate cancer, even if they are on feminizing hormone therapy.
• Screening and treatment follow the same principles, but hormone therapy considerations are more complex.
• A sensitive, respectful, and individualized approach is essential.

What If I Choose No Treatment at All?

• For low-risk disease, choosing active surveillance IS the recommended approach — it is not "doing nothing."
• For higher-risk disease, choosing no treatment is a personal decision that should be made with full understanding of the potential consequences. Your doctor can help you understand the natural history of your specific cancer.
• Palliative care and symptom management are always available regardless of treatment decisions.

Myth vs. Fact

Myth: "If I have prostate cancer, I need treatment right away."

Fact: For most prostate cancers, you have weeks to months to make a thoughtful decision. Rushing leads to regret. For low-risk disease, active surveillance (no immediate treatment) is the recommended approach.

Myth: "Surgery is better than radiation."

Fact: Multiple randomized trials with up to 15 years of follow-up show equivalent cancer control between surgery and radiation. The choice depends on side effects and personal values, not cancer outcomes.² ³ ⁴

Myth: "If my cancer has spread to the bones, there is nothing that can be done."

Fact: Modern combination therapies (ADT + ARPI ± chemotherapy) have dramatically improved survival for metastatic prostate cancer. Many men live for years with well-controlled metastatic disease.

Myth: "Hormone therapy alone is enough for metastatic prostate cancer."

Fact: ADT alone is no longer the standard of care. Adding an ARPI (abiraterone, enzalutamide, apalutamide, or darolutamide) significantly improves survival. ADT monotherapy is discouraged.

Myth: "Younger men should always get aggressive treatment."

Fact: Even in younger men, active surveillance is recommended for low-risk disease. A 2026 study showed that active surveillance is underutilized in young men despite guideline recommendations.⁴³

Myth: "If I have IBD, I cannot get radiation for prostate cancer."

Fact: Modern radiation techniques (IMRT, SBRT) can be used safely in most IBD patients. While flare rates may be slightly higher, serious complications are rare with current technology.⁴⁶ ⁴⁷

Questions to Ask Your Doctor

At Diagnosis:

1. What is my risk group, and what does it mean for my prognosis?
2. Do I need any additional tests (genomic testing, PET scan) before making a treatment decision?
3. Should I get a second opinion on my pathology?
4. Am I a candidate for active surveillance?
5. What is my estimated life expectancy, and how does that affect my treatment options?

About Treatment Options:

1. What are ALL my treatment options, including active surveillance?
2. What are the expected cancer control outcomes for each option?
3. What are the side effects of each option — short-term and long-term?
4. How will each option affect my urinary function, sexual function, and bowel function?
5. Do I need hormone therapy? If so, for how long?
6. Should I see both a urologist and a radiation oncologist before deciding?

About Metastatic Disease:

1. Is my disease low-volume or high-volume?
2. Am I a candidate for doublet or triplet therapy?
3. Should I receive radiation to the prostate even though my cancer has spread?
4. Am I a candidate for metastasis-directed therapy (MDT)?
5. Are there clinical trials I should consider?

About Follow-Up:

1. How often will my PSA be checked?
2. What PSA level would concern you?
3. What is a PSA bounce, and how will we tell it apart from recurrence?
4. What symptoms should prompt me to call your office?

Key Takeaways

• No two patients are the same. Treatment decisions depend on your risk group, life expectancy, baseline function, and personal values. There is no one-size-fits-all answer.
• See both a urologist AND a radiation oncologist before making your treatment decision. The type of doctor you see first strongly influences the treatment you receive.
• For low-risk disease, active surveillance is the recommended approach — not a compromise, but the evidence-based standard of care.
• For intermediate and high-risk disease, both surgery and radiation produce equivalent cancer control. The choice comes down to side effects and personal preference.
• For metastatic disease, ADT alone is no longer enough. Combination therapy with an ARPI (± chemotherapy for high-volume disease) is the standard of care and significantly improves survival.
• Radiation to the prostate improves survival in low-volume metastatic disease — even when cancer has spread.
• PSA monitoring after treatment is essential. Know what to expect: undetectable PSA after surgery, slow decline after radiation, and the possibility of a PSA bounce (which is NOT recurrence).
• You have time to decide. Do not rush. Get second opinions. Ask questions. Make the decision that is right for YOU.

Support Resources

• Prostate Cancer Foundation (PCF): pcf.org — comprehensive patient education, treatment guides, and research updates
• ZERO — The End of Prostate Cancer: zerocancer.org — support groups, educational resources, and a helpline
• Us TOO International: ustoo.org — peer-to-peer support and education for patients and families
• American Cancer Society: cancer.org — treatment decision tools and support services
• National Cancer Institute (NCI): cancer.gov — detailed treatment information and clinical trial search
• ClinicalTrials.gov: clinicaltrials.gov — search for clinical trials by cancer type and location
• Active Surveillance Patients International: aspatients.org — support specifically for men on active surveillance
• Prostate Cancer Research Institute (PCRI): pcri.org — educational resources and helpline
• Prostate Health Education Network (PHEN): prostatehealthed.org — resources specifically for African American men

Chapter 12 References

References

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Regional Prostate Cancer (PROS-7).
2. Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547–1558.
3. Hekman L, et al. A systematic review of clinical trials comparing radiation therapy versus radical prostatectomy in prostate cancer. Clin Genitourin Cancer. 2024;22(5):102157.
4. Fonteyne V, et al. Prostate cancer. Lancet. 2026;407(10528):622–636.
5. Raychaudhuri R, et al. Prostate cancer: a review. JAMA. 2025;333(16):1433–1446.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Androgen Deprivation Therapy — mCSPC (PROS-G).
7. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Metastasis-Directed Therapy (PROS-M).
9. Deek MP, et al. Metastasis-directed therapy in oligometastatic prostate cancer: an individual patient data meta-analysis of randomized trials (WOLVERINE). Lancet Oncol. 2025;26(5):653–662.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Workup and Treatment of mCSPC (PROS-13 through PROS-15).
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Androgen Deprivation Therapy (PROS-G).
12. Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
13. Raychaudhuri R, et al. Prostate cancer: a review. JAMA. 2025;333(16):1433–1446.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Monitoring (PROS-8).
15. Fonteyne V, et al. Prostate cancer. Lancet. 2026;407(10528):622–636.
16. Eastham JA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part II. J Urol. 2022;208(1):19–25.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Footnotes on PROS-9A.
18. Ali A, et al. Adding abiraterone or docetaxel to long-term hormone therapy in prostate cancer: directly randomised data from the STAMPEDE trial. Lancet Oncol. 2022;23(6):813–827.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Footnotes on PROS-8A.
20. Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249.
21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Treatment for First PSA Persistence/Recurrence After RP (PROS-9).
22. Parker CC, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998.
23. Fonteyne V, et al. Prostate cancer. Lancet. 2026;407(10528):622–636.
24. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Workup and Treatment of mCSPC.
25. Morgan TM, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline Part I. J Urol. 2024;211(4):509–517.
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Footnotes on PROS-9A.
27. Ost P, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): a randomized phase II trial. J Clin Oncol. 2018;36(5):446–453.
28. Fonteyne V, et al. Prostate cancer. Lancet. 2026;407(10528):622–636.
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Footnotes on PROS-8A (Phoenix definition).
30. Phillips R, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659.
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Principles of Radiation Therapy (PROS-J).
32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026. Treatment and Monitoring for Second BCR (PROS-12).
33. van As N, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer (PACE-B). N Engl J Med. 2024;391(15):1413–1425.
34. Nilsson P, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes. Lancet Oncol. 2026;27(3):293–301.
35. Tree AC, et al. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results. Lancet Oncol. 2025;26(7):936–947.
36. Deek MP, et al. Metastasis-directed therapy in oligometastatic prostate cancer: an individual patient data meta-analysis (WOLVERINE). Lancet Oncol. 2025;26(5):653–662.
37. Kim J, Feagins LA. Managing patients with inflammatory bowel disease who develop prostate cancer. Dig Dis Sci. 2020;65(1):22–30.
38. Caldera F, et al. AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with IBD. Clin Gastroenterol Hepatol. 2025;23(5):695–706.
39. Romano L, et al. Prostate and gut: any relationship? A narrative review. Prostate. 2024;84(6):513–524.
40. Kirk PS, et al. Implications of prostate cancer treatment in men with inflammatory bowel disease. Urology. 2017;104:131–136.
41. Wagle NS, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin. 2025;75(4):308–340.
42. Matsumoto K, et al. Establishment of the optimal follow-up schedule after radical prostatectomy. Urol Oncol. 2018;36(7):341.e9–341.e14.
43. Use of active surveillance in young men with low-risk prostate cancer. J Clin Oncol. 2026;44(suppl 7):abstr 404.
44. Romano L, et al. Prostate and gut: any relationship? Prostate. 2024;84(6):513–524.
45. Hammami MB, Mahadevan U. Men with inflammatory bowel disease: sexual function, fertility, medication safety, and prostate cancer. Am J Gastroenterol. 2020;115(4):526–534.
46. Lischalk JW, et al. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease. Radiat Oncol. 2021;16(1):126.
47. Feagins LA, et al. Rates of adverse IBD-related outcomes for patients with IBD and concomitant prostate cancer treated with radiation therapy. Inflamm Bowel Dis. 2020;26(5):728–733.
48. Burns JA, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019;75(5):846–852.